Importantly, targeting tumor antigens to Clec9A requires the co-administration of adjuvants, such as anti-CD40 or poly I:C, to induce effective Ag-specific CTLs; otherwise, it could result in tolerance [123]. Here, CLEC9A is linked to neoplasm.